

产品名称：氯甲苯噻嗪  
产品别名：Diazoxide；二氮嗪；Sch-6783；SRG-95213

生物活性：				
Description	Diazoxide (Sch-6783) is an ATP-sensitive potassium channel activator, can be used to treat hyperinsulinism.			
In Vitro	Diazoxide (Sch-6783) has a number of physiological effects, including lowering the blood pressure and rectifying hypoglycemia. Diazoxide has powerful protective properties against cardiac ischemia[1]. Diazoxide (Sch-6783) could protect NSC-34 neurons against the main sources of neurodegenerative damage. Diazoxide increases Nrf2 nuclear translocation in NSC-34 motoneurons and prevents endogenous oxidative damage[2].			
In Vivo	Diazoxide (Sch-6783) attenuates postresuscitation brain injury, protects mitochondrial function, inhibits brain cell apoptosis, and activates the PKC pathway by opening mitoKATP channels[3]. Treatment with Diazoxide (Sch-6783) in wild-type mice decreases intraocular pressure (IOP) by 21.5±3.2% with an absolute IOP reduction of 3.9 ± 0.6 mm Hg[4].			
Solvent&Solubility	<b>In Vitro:</b> <b>DMSO : ≥ 35 mg/mL (151.73 mM)</b> <b>H<sub>2</sub>O : &lt; 0.1 mg/mL (insoluble)</b> <small>* "≥" means soluble, but saturation unknown.</small>			
		<div>SolventMassConcentration</div>	1 mg	5 mg
	Preparing	1 mM	4.3352 mL	21.6760 mL
	Stock Solutions	5 mM	0.8670 mL	4.3352 mL
		10 mM	0.4335 mL	2.1676 mL
	*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80℃，6 months；-20℃，1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。			
	<b>In Vivo:</b> 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 <b>In Vitro</b> 方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶			
	1.请依序添加每种溶剂： 10% DMSO→40% PEG300 →5% Tween-80 → 45% saline Solubility: ≥ 2.67 mg/mL (11.57 mM); Clear solution 此方案可获得 ≥ 2.67 mg/mL (11.57 mM，饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 26.7 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀 向上述体系中加入 50 μL Tween-80，混合均匀；然后继续加入 450 μL 生理盐水定容至 1 mL。			
	2.请依序添加每种溶剂： 10% DMSO →90% corn oil Solubility: ≥ 2.67 mg/mL (11.57 mM); Clear solution 此方案可获得 ≥ 2.67 mg/mL (11.57 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。			

	以 1 mL 工作液为例, 取 100 $\mu$ L 26.7 mg/mL 的澄清 DMSO 储备液加到 900 $\mu$ L 玉米油中, 混合均匀。
<b>References</b>	<p>[1]. Coetzee WA, et al. Multiplicity of effectors of the cardioprotective agent, diazoxide. <i>Pharmacol Ther.</i> 2013 Nov;140(2):167-75.</p> <p>[2]. Virgili N, et al. K(ATP) channel opener diazoxide prevents neurodegeneration: a new mechanism of action viaantioxidative pathway activation. <i>PLoS One.</i> 2013 Sep 11;8(9):e75189.</p> <p>[3]. Wu H, et al. Diazoxide Attenuates Postresuscitation Brain Injury in a Rat Model of Asphyxial Cardiac Arrest by Opening Mitochondrial ATP-Sensitive Potassium Channels. <i>Biomed Res Int.</i> 2016;2016:1253842.</p> <p>[4]. Chowdhury UR, et al. ATP-sensitive potassium (K(ATP)) channel openers diazoxide and nicorandil lower intraocular pressure in vivo. <i>Invest Ophthalmol Vis Sci.</i> 2013 Jul 22;54(7):4892-9.</p>
<b>实验参考:</b>	
<b>Cell Assay</b>	<p>Diazoxide is dissolved in DMSO to prepare 50 mM stock solution. NSC-34 cells are allowed to differentiate for 8 weeks under reduced serum conditions and then seeded in 24-well plates. Glutamate is dissolved in culture medium and added to cultures at concentration of 10 <math>\mu</math>M for 24 h. Cell treatment with 100 <math>\mu</math>M diazoxide starts 2 h before glutamate exposure. Cell viability is measured by the MTT assay[2].</p>
<b>Animal Administration</b>	<p>Rats: Adult male Sprague-Dawley rats with induced cerebral ischemia (n=10 per group) receive an intraperitoneal injection of 0.1% DMSO (1 mL; vehicle group), diazoxide (10 mg/kg; DZ group), or diazoxide (10 mg/kg) plus 5-hydroxydecanoate (5 mg/kg; DZ + 5-HD group) 30 min after CPR. The control group (sham group, n=5) undergoes sham operation, without cardiac arrest. Mitochondrial respiratory control rate (RCR) is determined. Brain cell apoptosis is assessed using TUNEL staining. Expression of Bcl-2, Bax, and protein kinase C epsilon (PKC<math>\epsilon</math>) in the cerebral cortex is determined by Western blotting and immunohistochemistry[3].</p> <p>Mouse: Diazoxide is prepared by diluting a 100 mM stock solution in 10% polyethoxylated castor oil in PBS. In C57BL/6 wild-type and Kir6.2<sup>-/-</sup> mice, a 5 <math>\mu</math>L drop of 5 mM diazoxide is topically administered to one eye of each mouse while the fellow control eye received vehicle (DMSO and 10% polyethoxylated castor oil in the same proportion as the treated eye). IOP is measured daily at 1 hour, 4 hours, and 23 hours following treatment. Treatment with diazoxide and vehicle is continued daily for 14 consecutive days[4].</p>
<b>References</b>	<p>[1]. Coetzee WA, et al. Multiplicity of effectors of the cardioprotective agent, diazoxide. <i>Pharmacol Ther.</i> 2013 Nov;140(2):167-75.</p> <p>[2]. Virgili N, et al. K(ATP) channel opener diazoxide prevents neurodegeneration: a new mechanism of action viaantioxidative pathway activation. <i>PLoS One.</i> 2013 Sep 11;8(9):e75189.</p> <p>[3]. Wu H, et al. Diazoxide Attenuates Postresuscitation Brain Injury in a Rat Model of Asphyxial Cardiac Arrest by Opening Mitochondrial ATP-Sensitive Potassium Channels. <i>Biomed Res Int.</i> 2016;2016:1253842.</p> <p>[4]. Chowdhury UR, et al. ATP-sensitive potassium (K(ATP)) channel openers diazoxide and nicorandil lower intraocular pressure in vivo. <i>Invest Ophthalmol Vis Sci.</i> 2013 Jul 22;54(7):4892-9.</p>